Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial

医学 伊马替尼 中止 内科学 甲磺酸伊马替尼 中期分析 前瞻性队列研究 髓系白血病 外科 临床试验
作者
François‐Xavier Mahon,Delphine Réa,Joëlle Guilhot,François Guilhot,Françoise Huguet,Franck E. Nicolini,Laurence Legros,Aude Charbonnier,Agnès Guerci,Bruno Varet,Gabriel Étienne,Josy Reiffers,Philippe Rousselot
出处
期刊:Lancet Oncology [Elsevier BV]
卷期号:11 (11): 1029-1035 被引量:1501
标识
DOI:10.1016/s1470-2045(10)70233-3
摘要

Background Imatinib treatment significantly improves survival in patients with chronic myeloid leukaemia (CML), but little is known about whether treatment can safely be discontinued in the long term. We aimed to assess whether imatinib can be discontinued without occurrence of molecular relapse in patients in complete molecular remission (CMR) while on imatinib. Methods In our prospective, multicentre, non-randomised Stop Imatinib (STIM) study, imatinib treatment (of >2 years duration) was discontinued in patients with CML who were aged 18 years and older and in CMR (>5-log reduction in BCR–ABL and ABL levels and undetectable transcripts on quantitative RT-PCR). Patients who had undergone immunomodulatory treatment (apart from interferon α), treatment for other malignancies, or allogeneic haemopoietic stem-cell transplantation were not included. Patients were enrolled at 19 participating institutions in France. In this interim analysis, rate of relapse was assessed by use of RT-PCR for patients with at least 12 months of follow-up. Imatinib was reintroduced in patients who had molecular relapse. This study is registered with ClinicalTrials.gov, number NCT00478985. Findings 100 patients were enrolled between July 9, 2007, and Dec 17, 2009. Median follow-up was 17 months (range 1–30), and 69 patients had at least 12 months follow-up (median 24 months, range 13–30). 42 (61%) of these 69 patients relapsed (40 before 6 months, one patient at month 7, and one at month 19). At 12 months, the probability of persistent CMR for these 69 patients was 41% (95% CI 29–52). All patients who relapsed responded to reintroduction of imatinib: 16 of the 42 patients who relapsed showed decreases in their BCR–ABL levels, and 26 achieved CMR that was sustained after imatinib rechallenge. Interpretation Imatinib can be safely discontinued in patients with a CMR of at least 2 years duration. Imatinib discontinuation in this setting yields promising results for molecular relapse-free survival, raising the possibility that, at least in some patients, CML might be cured with tyrosine kinase inhibitors. Funding French Ministry of Health (Programme Hospitalier de Recherche 2006 grants), Institut National du Cancer (INCA).
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
Zhang完成签到,获得积分10
1秒前
2秒前
2秒前
3秒前
4秒前
圆锥香蕉给ZEcholy的求助进行了留言
5秒前
jisujun发布了新的文献求助10
5秒前
李小宁发布了新的文献求助10
5秒前
8秒前
Stroeve发布了新的文献求助10
9秒前
欧阳月空完成签到,获得积分10
9秒前
9秒前
星辰大海应助李小宁采纳,获得10
10秒前
段一帆发布了新的文献求助10
10秒前
冷艳的姿发布了新的文献求助10
10秒前
11秒前
FIN应助小小采纳,获得30
11秒前
领导范儿应助su采纳,获得10
12秒前
Candy发布了新的文献求助10
12秒前
Rondab应助xiaosu采纳,获得10
13秒前
CodeCraft应助LJJ采纳,获得10
14秒前
14秒前
SYLH应助科研通管家采纳,获得20
15秒前
所所应助科研通管家采纳,获得10
15秒前
科研通AI5应助科研通管家采纳,获得10
15秒前
张金蝶完成签到,获得积分10
15秒前
搜集达人应助科研通管家采纳,获得10
16秒前
CAOHOU应助科研通管家采纳,获得10
16秒前
丘比特应助科研通管家采纳,获得10
16秒前
CAOHOU应助科研通管家采纳,获得10
16秒前
赘婿应助科研通管家采纳,获得10
16秒前
量子星尘发布了新的文献求助30
16秒前
SYLH应助科研通管家采纳,获得20
16秒前
16秒前
16秒前
16秒前
CAOHOU应助科研通管家采纳,获得10
16秒前
Lyuhng+1完成签到 ,获得积分10
17秒前
大个应助十九岁的时差采纳,获得10
18秒前
高分求助中
A new approach to the extrapolation of accelerated life test data 1000
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
‘Unruly’ Children: Historical Fieldnotes and Learning Morality in a Taiwan Village (New Departures in Anthropology) 400
Indomethacinのヒトにおける経皮吸収 400
Phylogenetic study of the order Polydesmida (Myriapoda: Diplopoda) 370
基于可调谐半导体激光吸收光谱技术泄漏气体检测系统的研究 350
Robot-supported joining of reinforcement textiles with one-sided sewing heads 320
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3989334
求助须知:如何正确求助?哪些是违规求助? 3531428
关于积分的说明 11253936
捐赠科研通 3270119
什么是DOI,文献DOI怎么找? 1804887
邀请新用户注册赠送积分活动 882087
科研通“疑难数据库(出版商)”最低求助积分说明 809173